Worth reading
51Recurring
Scored from 4 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
1600
¥ million (transfer amount)Wording
Conditional
How definitive the wording is.This transaction
This share transferCounterparty株式会社エムティーアイ・ヘルスケア・ホールディングス
Disclosing companyMTI Ltd.
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
TimelineThe spacing between the points is proportional to the actual number of days.
Target company
Provision of business systems for dispensing pharmacies
Location Shinjuku-ku, TokyoShare capital ¥100 millionDate of incorporation 1 March 2022
Consideration and expenses
Acquisition price¥1,600 million
Amount of extraordinary income (loss)Gain on sale of shares in an affiliated company: ¥802 million (non-consolidated financial statements for the fourth quarter of the fiscal year ending September 2026)
Impact on Business Performance
The impact on the full-year consolidated earnings forecast will be minor because the extraordinary gain will be eliminated on consolidation.
Procedures and assumptions
Management structure after acquisitionAfter the transfer, HCHD will hold 98.77%. Information regarding the corporate name, representative and treatment of employees is Not disclosed.
| Item | Details |
|---|---|
| Transaction name | This share transfer |
| Counterparty name | 株式会社エムティーアイ・ヘルスケア・ホールディングス |
| Name of the Subject Company | 株式会社イーグル |
| Business Description of the Subject Company | Provision of business systems for dispensing pharmacies |
| Location of the Subject Company | Shinjuku-ku, Tokyo |
| Capital Stock of the Subject Company | ¥100 million |
| Date of Establishment of the Subject Company | 1 March 2022 |
| Acquisition price | ¥1,600 million |
| Number of shares acquired | All shares held by the Company (number of shares and voting rights: Not disclosed) |
| Voting rights ownership percentage | Before 98.77% (the Company) → after 0% (the Company; HCHD will hold 98.77% after the transfer) |
| Amount of extraordinary income (loss) | Gain on sale of shares in an affiliated company: ¥802 million (non-consolidated financial statements for the fourth quarter of the fiscal year ending September 2026) |
| Impact on Business Performance | The impact on the full-year consolidated earnings forecast will be minor because the extraordinary gain will be eliminated on consolidation. |
| Date of board resolution | 17 July 2026 |
| Execution Date / Effective Date | 31 July 2026 |
| Management structure after acquisition | After the transfer, HCHD will hold 98.77%. Information regarding the corporate name, representative and treatment of employees is Not disclosed. |
Items this document does not state (17)
Net Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodFunding arrangementsGoodwill amountContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to Execution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen collaboration with 株式会社ソラミチシステム and other companies under HCHD in the pharmacy DX business on which the Company is focusing.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.